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Background: The primary PCI (PPCI)is the recommended method of revascularisation of IRA in patients with acute myocardial infarction(AMI). But 
we have only few data over long time efficacy and safety of DES in PPCI scenarios.
Methods: We enclosed 300 patients with PPCI in AMI between 2002 and 2005. Respectively 150 patients were treated with DES (Cypher) or 
BMS. Both patient’s groups did not differ relevant with regard to comorbidity or demography. All patients received a state kind therapy with aspirin, 
heparin, glycoprotein IIb/IIIa receptor antagonists and Clopidogrel. The Follow-up investigation occurred 5.4-5.9 years after primary PCI.
Results: table 1
Conclusions:  DES-implantation in primary PCI of patients with AMI reduces in 5years FU the TVR- and MACE rates significantly. However,the 
patients with DES have a significantly raised risk of very late stenthrombosis. No difference between BMS and DES we find in terms of long time-
mortality and EF over more than 5 years.
Results
DES (n=150) BMS (n=150) p (OR/95% CI)
Male
Age
123 (82%) 117 (78%) n.s.
Diabetes mellitus
Hypertension
HLP
18 (12%)
120 (80%)
123 (82%)
27 (18%)
114 (76%)
120 (80%)
n.s.
n.s.
n.s.
STEMI 105 (70%) 107 (71%) n.s.
5-year death 12 (8%) 18 (12%) 0.54 1.7(0.45-6.50)
5-year cardial death 3 (2%) 9 (6%) 0.08 2.3(0.89-3.25)
5-year Re-MI 12 (8%) 12 (8%) 1.00 1.1(0.26-4.70)
5-year TVR 6 (4%) 30 (20%) <0.01 6.6(1.4-32.2)
5-year MACE 24 (16%) 51 (34%) 0.03 4.2(1.02-16.53)
5-year Stentthrombosis
early
very late
4 (2.7%)
1 (0.7%)
3 (2%)
1 (0.7%)
1 (0.7%)
0
0.03 2.8(1.09-7.62)
